18:50:06 EST Mon 16 Nov 2026
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save
Vector Science and Therapeutics Corp
Symbol PAIN
Shares Issued 157,322,930
Close 2026-11-16 C$ 3.13
Market Cap C$ 492,420,771
Recent Sedar+ Documents

Vector Science to hold media briefing Nov. 18

2026-11-16 18:11 ET - News Release

Mr. Tommy Thompson reports

SPORTS MEDICINE PIONEER DR. JAMES ANDREWS AND VECTOR CHAIRMAN TOMMY THOMPSON, FORMER U.S. SECRETARY OF HEALTH AND HUMAN SERVICES, TO ANNOUNCE MAJOR MEDICAL DEVELOPMENT INVOLVING PEPTIDES

Dr. James Andrews, a world-renowned orthopedic surgeon and sports medicine pioneer, and Tommy G. Thompson, the former U.S. secretary of health and human services and current chairman of Vector Science and Therapeutics Corp., will host a livestreamed media briefing from Gulf Breeze, Fla., on Wednesday, Nov. 18. Dr. Andrews and Mr. Thompson will announce a major medical development involving peptides in the United States.

Livestreamed media briefing information

Date:  Wednesday, Nov. 18, 2026

Time:  11 a.m. to 11:30 a.m. CST

Format:  live Zoom event originating in Gulf Breeze, Fla.

Please register for event access.

Journalists and other audience members should use the Zoom link above to preregister. Following registration, attendees will receive the information needed to access the live event.

Media interview scheduling and co-ordination

Immediately following the briefing, from 11:30 a.m. CST until 12:30 p.m. CST on Wednesday, Dr. Andrews, Mr. Thompson and other briefing participants will be available to conduct media interviews by Zoom or telephone. Interview requests and scheduling will be handled through the chat function during the Zoom event or by e-mail using VectorPR@russopartnersllc.com. Journalists who are unable to conduct interviews during this window may request additional times, and Russo Partners will manage these requests individually.

About Vector Science and Therapeutics Corp.

Vector Science is a medical technology company advancing anatomically focused drug delivery technology and current good manufacturing practice manufactured Rx peptides for the sports medicine, regenerative medicine, pain management and wound care markets. Vector's peptides are manufactured using pharma-grade active pharmaceutical ingredients from qualified suppliers, and are produced under current good manufacturing practice and ISO-certified quality systems.

The company's product and intellectual property portfolio includes advanced transdermal delivery, precision catheter systems and smart wound care technologies. Vector is headquartered in Mequon, Wis.

© 2026 Canjex Publishing Ltd. All rights reserved.